mexiletine has been researched along with Disease Exacerbation in 1 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Excerpt | Relevance | Reference |
---|---|---|
"To determine the safety and tolerability of mexiletine in a phase II double-blind randomized controlled trial of sporadic amyotrophic lateral sclerosis (SALS)." | 9.22 | A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. ( Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016) |
"To determine the safety and tolerability of mexiletine in a phase II double-blind randomized controlled trial of sporadic amyotrophic lateral sclerosis (SALS)." | 5.22 | A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. ( Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Weiss, MD | 1 |
Macklin, EA | 1 |
Simmons, Z | 1 |
Knox, AS | 1 |
Greenblatt, DJ | 1 |
Atassi, N | 1 |
Graves, M | 1 |
Parziale, N | 1 |
Salameh, JS | 1 |
Quinn, C | 1 |
Brown, RH | 1 |
Distad, JB | 1 |
Trivedi, J | 1 |
Shefner, JM | 1 |
Barohn, RJ | 1 |
Pestronk, A | 1 |
Swenson, A | 1 |
Cudkowicz, ME | 1 |
1 trial available for mexiletine and Disease Exacerbation
Article | Year |
---|---|
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Dose-Response Relationship, Drug; Female; Follow | 2016 |